AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36104128
Drug: Placebo capsule,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule, for 14 days
Trial: 34229051
Drug: NIMO‐CCRT (CCRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIMO‐CCRT (CCRT with 200 mg of nimotuzumab administered weekly by intravenous infusion)
Trial: 34229051
Drug: CCRT (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCRT (65 Gy thoracic radiation over 5 weeks concurrent with docetaxel and cisplatin)
Trial: 33253664
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection 2 mg every 4 weeks (2q4)
Trial: 33253664
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection 2 mg every 8 weeks (2q8)
Trial: 33759389
Drug: Phenotype-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenotype-guided treatment with antiobesity medications (phentermine, phentermine/topiramate, bupropion/naltrexone, lorcaserin, liraglutide)
Trial: 33759389
Drug: Non-phenotype-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-phenotype-guided treatment with antiobesity medications
Trial: 35963206
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine treatments)
Trial: 32031726
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of MMR vaccine
Trial: 37804858
Drug: Faster-acting insulin
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Faster-acting insulin aspart (faster aspart)
Trial: 32332810
Drug: Motor Imagery
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motor Imagery (MI) training for 25 minutes prior to 65 minutes of Structured Progressive Circuit Class Therapy (SPCCT)
Trial: 32332810
Drug: Health Education
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health Education (HE) for 25 minutes prior to 65 minutes of Structured Progressive Circuit Class Therapy (SPCCT)
Trial: 36041708
Drug: Colchicine 1
RxNorm normalized name: colchicine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 1 mg on days 1-7, 0.5 mg on days 8-14
Trial: 36041708
Drug: Colchicine 0.5
RxNorm normalized name: colchicine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5 mg per day for 14 days
Trial: 36041708
Drug: Colchicine 2
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine 2 mg on day 1, 1 mg on days 2-7, 0.5 mg on days 8-14
Trial: 36041708
Drug: Colchicine 3
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine 3 mg on day 1, 1 mg on days 2-7, 0.5 mg on days 8-14
Trial: 33704936
Drug: One-step screening
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-step screening (75-g glucose load, fasting state)
Trial: 33704936
Drug: Two-step screening
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two-step screening (50-g glucose load, nonfasting state followed by 100-g glucose load, fasting state)
Trial: 32856709
Drug: Low salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low salt diet (1,500 mg/d)
Trial: 32856709
Drug: Medium salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium salt diet (2,400 mg/d)
Trial: 32856709
Drug: High salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High salt diet (3,300 mg/d)
Trial: 35378544
Drug: Intensive mirror
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive mirror therapy (5 times/week for 6 weeks)
Trial: 35378544
Drug: Spaced mirror
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spaced mirror therapy (3 times/week for 10 weeks)
Trial: 33128635
Drug: DS‐25OHD <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS‐25OHD < 40 nmol/L
Trial: 35230249
Drug: Community volunteers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community volunteers (CVs) tracking children's vaccination status and demographic movements, organizing monthly catch-up immunization sessions via WhatsApp.
Trial: 33818221
Drug: Horticultural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horticultural therapy (HT)
Trial: 35509819
Drug: Red ginseng
RxNorm normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red ginseng formulation
Trial: 35509819
Drug: Red ginseng
RxNorm normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red ginseng formulation with 1,2‐hexanediol
Trial: 35509819
Drug: Hydrogel formulation
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel formulation
Trial: 32890813
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (more than six cycles)
Trial: 34695622
Drug: Pharmaceutical method
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical method (prostaglandins)
Trial: 33367539
Drug: Orthodontic space
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orthodontic space closure treatment (TG)
Trial: 32613752
Drug: Cinpanemab (BIIB054)
RxNorm normalized name: Cinpanemab
DrugBank: Cinpanemab (DB16127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinpanemab (BIIB054) 250 mg every 4 weeks
Trial: 32613752
Drug: Cinpanemab (BIIB054)
RxNorm normalized name: Cinpanemab
DrugBank: Cinpanemab (DB16127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinpanemab (BIIB054) 1,250 mg every 4 weeks
Trial: 32613752
Drug: Cinpanemab (BIIB054)
RxNorm normalized name: Cinpanemab
DrugBank: Cinpanemab (DB16127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinpanemab (BIIB054) 3,500 mg every 4 weeks
Trial: 32613752
Drug: Cinpanemab (BIIB054)
RxNorm normalized name: Cinpanemab
DrugBank: Cinpanemab (DB16127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinpanemab (BIIB054) up to 90 mg/kg
Trial: 32812388
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (0.25 mg/kg)
Trial: 32619413
Drug: Immunomodulator therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulator therapy (in addition to allocated treatment)
Trial: 35902900
Drug: Prebiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic treatment 1
Trial: 35902900
Drug: Prebiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic treatment 2
Trial: 35902900
Drug: Prebiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic treatment 3
Trial: 35902900
Drug: Prebiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic treatment 1, 2, and 3
Trial: 33097554
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of local anaesthetic
Trial: 33097554
Drug: Intravenous analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous analgesia with or without sedation
Trial: 35210352
Drug: Bedtime antihypertensive
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime antihypertensive administration
Trial: 35210352
Drug: Morning antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning antihypertensive administration
Trial: 32862009
Drug: Anodal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodal treatment group (tsDCS)
Trial: 32862009
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment group
Trial: 33865501
Drug: Teprotumumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teprotumumab (10 mg/kg body weight for the first infusion, 20 mg/kg for subsequent infusions, administered every 3 weeks for a total of 8 infusions)
Trial: 34275830
Drug: Propofol dosing
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol dosing based on lean body weight (LBW)
Trial: 32854693
Drug: Invisalign treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invisalign treatment (Control)
Trial: 84056285
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral diazepam and supportive care (n = 25)
Trial: 84056285
Drug: Further (unblinded)
RxNorm normalized name: HOMOSALATE 10 g in 100 mL / OCTOCRYLENE 7 g in 100 mL / OCTISALATE 5 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL LOTION [CO-BB-54431 Featuring You Hydrating Skin Enhancing Tint SPF30-270 FURTHER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Further (unblinded) diazepam, 20 mg, every 1 to 2 hr for non-responders (n = 18)
Trial: 84056285
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg diazepam doses
Trial: 35065063
Drug: Ceftriaxone (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (500 mg, intramuscular)
Trial: 35065063
Drug: Ertapenem (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem (1000 mg, intramuscular)
Trial: 35065063
Drug: Gentamicin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (5 mg/kg, maximum 400 mg, intramuscular)
Trial: 35065063
Drug: Fosfomycin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin (6 g, oral)
Trial: 34711192
Drug: sugammadex 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugammadex 16 mg/kg
Trial: 33866311
Drug: Wet cupping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wet cupping plus 500 mg azithromycin 3 times/week for 12 weeks
Trial: 33866311
Drug: Sham cupping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham cupping plus 500 mg azithromycin 3 times/week for 12 weeks
Trial: 35412430
Drug: Adjuvant irinotecan-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant irinotecan-based therapy (IFL)
Trial: 35412430
Drug: Adjuvant irinotecan-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant irinotecan-based therapy (IFL) in patients with unDCR1 and KRAS-wildtype tumours
Trial: 32452549
Drug: Lanadelumab 150
RxNorm normalized name: Lanadelumab 150 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanadelumab 150 mg every 4 weeks
Trial: 32452549
Drug: Lanadelumab 300
RxNorm normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanadelumab 300 mg every 4 weeks
Trial: 39128590
Drug: Lanadelumab 300
RxNorm normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanadelumab 300 mg every 2 weeks
Trial: 32452549
Drug: Lanadelumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanadelumab (all doses)
Trial: 35343430
Drug: New sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New sodium valproate formulation (epilenil 500-mg coated tablet)
Trial: 33098330
Drug: Tablet with
RxNorm normalized name: Oral Tablet with Sensor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet with video games (control group)
Trial: 34781221
Drug: Traditional Swallowing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Swallowing Therapy (TST) and Neuromuscular Electrical Stimulation (NMES)
Trial: 34781221
Drug: Traditional Swallowing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Swallowing Therapy (TST) and Kinesiology Taping (KT)
Trial: 34781221
Drug: Traditional Swallowing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Swallowing Therapy (TST), Neuromuscular Electrical Stimulation (NMES), and Kinesiology Taping (KT)
Trial: 35392979
Drug: targeted Mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: targeted Mass Drug Administration (tMDA)
Trial: 34091276
Drug: Combined CPT
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined CPT and Cognitive Symptom Management and Rehabilitation Therapy (SMART-CPT)
Trial: 32985396
Drug: Group activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group activity with Paro (robotic seal) for 30 minutes twice a week over 12 weeks
Trial: 32621874
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (50,000 IU weekly for the first month, followed by 2000 IU daily)
Trial: 36484691
Drug: Interactive Voice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive Voice Response Cognitive Behavioral Therapy for Chronic Pain (IVR CBT-CP)
Trial: 33032770
Drug: IV golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV golimumab 2 mg/kg at weeks 0, 4, and 12, and every 8 weeks thereafter
Trial: 36184697
Drug: Mepolizumab (3-24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab (3-24 mg) and Reslizumab (0.1-0.8 mg/kg)
Trial: 35345367
Drug: Twice application
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice application of 85% TCA (n=27)
Trial: 36181056
Drug: Curcuminoids at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids at 1500 mg per day for 3 days before and 2 days after the procedure
Trial: 33821899
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg orally daily for 3 years)
Trial: 36217848
Drug: COVID-19 vaccination
RxNorm normalized name: COVID-19 VACCINE ADENOVIRUS-26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 vaccination (2nd dose)
Trial: 33421560
Drug: Subcutaneous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous tissue disinfection with povidone-iodine solution
Trial: 33421560
Drug: Subcutaneous disinfection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous disinfection protocol
Trial: 32020438
Drug: SEQ tremelimumab
RxNorm normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEQ tremelimumab 75 mg IV over 1 h followed by durvalumab 1500 mg IV over 1 h q4wks
Trial: 32020438
Drug: CON administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CON administration of durvalumab and tremelimumab over 1 h
Trial: 33009066
Drug: Intrasphincteric BoNTA
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrasphincteric BoNTA injection (n = 30)
Trial: 33480241
Drug: HCM (1.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCM (1.5, 3.0 and 6.0 g/kg)
Trial: 33480241
Drug: HCM (6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCM (6.0 g/kg)
Trial: 32981268
Drug: Urtica Dioica
RxNorm normalized name: Urtica Dioica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urtica Dioica root extract (UDE) 450 mg day‐1 for 12 weeks
Trial: 35565243
Drug: Naldemedine (NAL)
DrugBank: Naldemedine (DB11691)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Naldemedine (NAL) 0.2 mg, once daily
Trial: 35565243
Drug: Magnesium Oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium Oxide (MgO) 500 mg, thrice daily
Trial: 36454569
Drug: Esketamine infusion
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Esketamine infusion (0.3 mg/kg/h)
Trial: 33677986
Drug: Tenofovir treatment
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir treatment
Trial: 34562067
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 200-600 mg of RO7049389
Trial: 34562067
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of 200-400 mg of RO7049389
Trial: 34562067
Drug: Placebo (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (multiple ascending doses)
Trial: 33484934
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg daily subcutaneous injection)
Trial: 33371157
Drug: Behavioral cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral cognitive therapy technology (sleep hygiene and cognitive therapy)
Trial: 32842825
Drug: LSD 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSD 20 µg
Trial: 36196515
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) using a 940 nm diode laser before dental injection
Trial: 35652771
Drug: Posterior Capsule
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior Capsule (PC) approach
Trial: 32231293
Drug: FEC14 (fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC14 (fluorouracil, epirubicin and cyclophosphamide administered every 2 weeks)
Trial: 32231293
Drug: FEC21 (fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC21 (fluorouracil, epirubicin and cyclophosphamide administered every 3 weeks)
Trial: 32231293
Drug: FEC14 (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC14 (in hormone receptor-negative tumours)
Trial: 32231293
Drug: FEC21 (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC21 (in hormone receptor-negative tumours)
Trial: 32312333
Drug: Garlic powder
RxNorm normalized name: Garlic Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic powder supplementation (400 mg per tablet, 4 tablets daily)
Trial: 32312333
Drug: Placebo (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (400 mg starch per tablet, 4 tablets daily)
Trial: 34922726
Drug: Paracetamol 500
RxNorm normalized name: Paracetamol 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 500 mg plus Codeine 30 mg (group APAP/COD)
Trial: 34922726
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg (group IBU)
Trial: 35562226
Drug: i.v. bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. bolus remimazolam (0.02–0.27 mg kg−1)
Trial: 32126267
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel (20 mg/m2) with postoperative radiation therapy (total dose 60-66 Gy)
Trial: 35926726
Drug: Hexavalent live
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexavalent live human-bovine reassortant rotavirus vaccine (HRV)
Trial: 32031889
Drug: MK-2206 135
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-2206 135 mg/week
Trial: 32031889
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard taxane- and anthracycline-based neoadjuvant therapy)
Trial: 36193841
Drug: Baseline insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baseline insulin level
Trial: 33058798
Drug: Cefiderocol 2
RxNorm normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cefiderocol 2 g every 8 hours for 7–14 days
Trial: 33058798
Drug: Meropenem 2
RxNorm normalized name: meropenem 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 2 g every 8 hours for 7–14 days
Trial: 34376180
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) TXA
Trial: 34376180
Drug: TXA in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA in a PAMC injection for topical administration
Trial: 34376180
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both intravenous and topical administration of TXA
Trial: 39326583
Drug: Upadacitinib 45
RxNorm normalized name: upadacitinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 45 mg
Trial: 33646842
Drug: Slow continuous
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow continuous infusion of hypertonic saline
Trial: 36078774
Drug: Training (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training (16 weeks of combined training including walking/running at 63% of V˙O2max, three times per week, and strength training, consisting of one set of fifteen repetitions at moderate intensity, twice per week)